Effluxes of 3,4-Dihydroxyphenylalanine, 3,4-Dihydroxyphenylglycol, and Norepinephrine from Four Blood Vessels During Basal Conditions and During Nerve Stimulation

Abstract: Effluxes of 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenyglycol, and norepinephrine from four superfused canine blood vessels (saphenous and portal veins and mesenteric and pulmonary arteries) were studied under basal conditions and during nerve stimulation. From quantification of the compounds a series of indices of activities at neuroeffector junctions are proposed. These are (a) basal overflow of 3,4-dihydroxyphenylglycol as an index of vesicular-cytoplasmic translocation of norepinephrine, (b) the increase in 3,4-dihydroxyphenyglycol overflow attributable to nerve stimulation as an index of neuronal reuptake of norepinephrine released by stimulation, (c) the sum of the increases in overflows of norepinephrine and 3,4-dihydroxyphenylglycol attributable to nerve stimulation as an index of evoked release of norepinephrine, and (d) the efflux of 3,4-dihydroxyphenylalanine as an index of the activity of tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of norepinephrine. There were clear differences between these indices in the vessels. Correlation coefficients of the indices among vessels indicated that a high tissue norepinephrine level was associated with high biosynthetic capacity and high vesicular-cytoplasmic exchange but not with high release. There was no evidence suggesting feedback inhibition of synthesis by neuroplasmic norepinephrine—whether arising from vesicular-cytoplasmic translocation or from reuptake from the junctional cleft. The major value of these indices will probably be in determining the intergrated effects of pharmacologic agents at neuroeffector junctions in different blood vessels.     

Precursors and Metabolites of Norepinephrine in Sympathetic Ganglia of the Dog

3,4-Dihydroxyphenylalanine, dopamine, epinephrine, 3,4-dihydroxyphenylglycol, and 3,4-dihydroxyphenylacetic acid as well as norepinephrine were measured in dog lumbar sympathetic ganglia. The responses of these compounds to several classes of stimuli were investigated using an isolated time-resolved superfusion system. Nonselective (i.e., amphetamine and high K+) and receptor-mediated selective (oxotremorine) stimuli were used to evoke releases. The overflows of all compounds were measured by HPLC with electrochemical detection. The efficiency of each stimulus was estimated by normalizing the amount of evoked release to the total neurotransmitter pool when the stimulus was applied; i.e., fractional release was calculated. Overflows of all compounds except 3,4-dihydroxyphenylalanine were enhanced by a 10-min 100 microM amphetamine stimulus, and each of the catecholamine pools (dopamine, norepinephrine, and epinephrine) was affected to the same degree. By contrast, the 3,4-dihydroxyphenylalanine and dopamine pools were more readily releasable than the norepinephrine pool with a 10-min 80 mM K+ stimulus, and these releases were Ca2+ dependent. Epinephrine was released in preference to norepinephrine by a 10-min 1 mM oxotremorine stimulus. The data suggest the existence of at least three types of neurons in dog lumbar ganglia and are consistent with previous histological observations.     

Simultaneous analysis of human plasma catecholamines by high-performance liquid chromatography with a reversed-phase triacontylsilyl silica column

The clinical importance of simultaneous analysis of 3,4-dihydroxyphenylglycol with other human plasma catecholamines has been investigated to better understand the sympathetic nervous system. However, previous reports have had analytical difficulties with both resolution and extraction. The current study uses a reversed-phase triacontylsilyl silica (C30) column under the mobile phase condition without ion-pair reagents to separate catecholamines and their metabolites, with above 91% recoveries for intra-assay, above 85% for inter-assay, and less than 10% (n=5) coefficient of variation. Lower detection limits (S/N=4) and quantification limits (S/N=6) were 40 and 100 pg/mL for norepinephrine, 3,4-dihydroxyphenylglycol, and 3,4-dihydroxyphenylalanine, 10 and 20 pg/mL for epinephrine, 10 and 40 pg/mL for dopamine. Linear ranges were from 40 to 5000 pg/mL for norepinephrine and 3,4-dihydroxyphenylalanine, from 100 to 5000 pg/mL for 3,4-dihydroxyphenylglycol, and from 10 to 2000 pg/mL for epinephrine and dopamine. The C30 column may prove clinically useful, as it provides a convenient and simultaneous method of evaluation of human plasma catecholamines.     

Endogenous Noradrenaline and Dopamine in Nerve Terminals of the Hippocampus: Differences in Levels and Release Kinetics

The presence and release of endogenous catecholamines in rat and guinea pig hippocampal nerve terminals was studied by fluorimetric HPLC analysis. In isolated nerve terminals (synaptosomes) the levels and breakdown of endogenous catecholamines were determined and the release process was characterized with respect to its kinetics and Ca2+ and ATP dependence. Endogenous noradrenaline and dopamine, but not adrenaline, were detected in isolated hippocampal nerve terminals. For dopamine both the levels and the amounts released were more than 100-fold lower than those for noradrenaline. In suspension, released endogenous catecholamines were rapidly broken down. This could effectively be blocked by monoamine oxidase inhibitors, Ca(2+)-free conditions, and glutathione. The release of both noradrenaline and dopamine was highly Ca2+ and ATP dependent. Marked differences were observed in the kinetics of release between the two catecholamines. Noradrenaline showed an initial burst of release within 10 s after K+ depolarization. The release of noradrenaline was terminated after approximately 3 min of K+ depolarization. In contrast, dopamine release was more gradual, without an initial burst and without clear termination of release within 5 min. It is concluded that both catecholamines are present in nerve terminals in the rat hippocampus and that their release from (isolated) nerve terminals is exocytotic. The characteristics of noradrenaline release show several similarities with those of other classical transmitters, whereas dopamine release characteristics resemble those of neuropeptide release in the hippocampus but not those of dopamine release in other brain areas. It is hypothesized that in the hippocampus dopamine is released from large, dense-cored vesicles, probably colocalized with neuropeptides.     

Nerve impulse-induced release of endogenous noradrenaline and adrenaline from the perfused cod spleen

Summary Release of endogenous catecholamines (CA) by electrical nerve stimulation (NS) was studied in the isolated perfused spleen of the Atlantic cod,Gadus morhua. An HPLC-system for the analysis of endogenously released CA is described. Cocaine (COC) was used to block neuronal re-uptake of endogenous CA released by NS. Splanchnic NS at frequencies of 1–40 Hz for 20 s resulted in release of noradrenaline (NA) and adrenaline (A) with a maximal total overflow at 20 Hz for both amines. The release of CA was frequency-dependent. COC (0.1 mmol·l^-1) increased NS-evoked (40 Hz) overflow of NA and A by 4.8 and 2.2 times, respectively, and reduced the overflow of dihydroxyphenylglycol (DOPEG) to spontaneous efflux levels or less. It can be concluded that the HPLC-technique used was adequate for measurement of NS-evoked release of endogenous CA and DOPEG from the isolated perfused cod spleen, and the model presented can therefore be used when studying adrenergic mechanisms in fish spleen.Abbreviations A adrenaline - CA catecholamines - COC cocaine - DA dopamine - DHBA 3,4-dihydroybenzylamine hydrobromide - DOPAC 3,4-dihydroxyphenylacetic acid - DOPEG 3,4-dihydroxyphenylglycol - l-DOPA 3,4-dihydroxyphenylalanine - NA noradrenaline - NS nerve stimulation - PCA perchloric acid     

Adrenomedullary Secretion of DOPA, Catecholamines, Catechol Metabolites, and Neuropeptides

Abstract: Catecholamines and their metabolites have been proposed as markers of sympathetic nervous system stimulation. However, the adrenal medulla is a rich source of catecholamines and catecholamine metabolites and may play a significant role in plasma levels of these compounds. In addition to adrenal catecholamine metabolite efflux, the role of the catecholamine precursor 3,4-dihydroxyphenylalanine (DOPA) has not been fully evaluated. The simultaneous effluxes of catecholamines, metabolites, DOPA, and neuropeptides were measured in perfusates from isolated dog adrenals. The relative abundance of compounds detected consistently during unstimulated conditions was epinephrine ≫ norepinephrine > 3,4-dihydroxyphenylglycol > metanephrine > normetanephrine > dopamine > 3,4-dihydroxyphenylacetic acid > 3-methoxy-4-hydroxyphenylglycol ≥ DOPA ≫ [Met]enkephalin ≫ neuropeptide Y. Effluxes of analytes were not affected by cocaine and the ratios of catecholamines to metabolites increased dramatically with carbachol stimulation, consistent with negligible reuptake into adrenal cells. Thus, most of the 3,4-dihydroxyphenylglycol is expected to be derived from epinephrine and norepinephrine subsequent to translocation from chromaffin vesicles into the cytosol. The efflux of DOPA increased dramatically during stimulation with 30 µ M carbachol in a calcium-dependent manner. Efflux of DOPA during the initial stabilization period of the perfusion preparation declined exponentially, in parallel with the effluxes of the catecholamines and neuropeptides but not with metabolites. Evoked release of DOPA was Ca²⁺-dependent. These data suggest that DOPA can be stored and released exocytotically from chromaffin granules.     

Release of dopamine beta-hydroxylase and chromogranin A upon stimulation of the splenic nerve

Two proteins present in noradrenergic vesicles of the splenic nerve (dopamine beta-hydroxylase and chromogranin A) are released into the perfusate from the spleen when the splenic nerve is stimulated. Experiments in which drugs were added to the perfusion fluid showed that the proteins were released from terminals of the splenic nerve. There was a correlation between the amounts of the proteins released and the quantity of noradrenaline released; and the release process was dependent upon calcium. It is suggested that the proteins are released from the large dense-cored vesicles present in the terminals of the splenic nerve, and that secretion from these vesicles occurs by exocytosis.     

Transmitter-Like Basal and K+-Evoked Release of 3,4-Dihydroxyphenylalanine from the Striatum in Conscious Rats Studied by Microdialysis

Using microdialysis and HPLC, characteristics of the release of endogenous 3,4-dihydroxyphenylalanine (DOPA) from striatum in conscious rats were studied in comparison with those of 3,4-dihydroxyphenylethylamine (dopamine; DA). Purified L-aromatic amino acid decarboxylase (AADC) converted a putative peak of DOPA to DA. The retention time of DOPA differed from that of DA and major metabolites of DA and norepinephrine. The DOPA peak of dialysates comigrated with that of authentic DOPA when the pH of the HPLC buffer was modified. The ratio of the basal release of DOPA:DA was 1:2. 3-Hydroxybenzylhydrazine (NSD-1015; 100 mg/kg, i.p.), an AADC inhibitor, markedly increased the basal release of DOPA but produced no effect on DA. The basal release of DOPA was markedly decreased by alpha-methyl-p-tyrosine (200 mg/kg, i.p.), substantially tetrodotoxin (1 microM) sensitive, and Ca2+ (removal plus 12.5 mM Mg2+ addition) dependent. Fifty millimolar K+ released DOPA and this release was also Ca2+ dependent. These characteristics of the basal and evoked release of DOPA were similar to those of DA. The ratio of the evoked release of DOPA:DA was 1:3. These results indicate that DOPA is released under physiological conditions and by K(+)-induced depolarization in a manner similar to that for transmitter DA from striatum in freely moving rats.     

Concentrations of 3,4-Dihydroxyphenylalanine and Catecholamines and Metabolites in Brain in an Anhepatic Model of Hepatic Encephalopathy

Abstract: Alterations in the catecholaminergic neurotransmitter systems have been shown to occur in hepatic failure and may contribute to development of hepatic encephalopathy. In the present study we used the rat after complete hepatectomy as a model for study of changes that occur in brain in acute liver failure. We attempted to identify processes in the synthesis, storage, and metabolism of catecholamine neurotransmitters that might be changed during liver failure by measuring levels of, together with those of norepinephrine and dopamine, the precursor (3,4-dihydroxyphenylalanine) and the neuronal metabolites of dopamine and norepinephrine (3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol, respectively) in different regions of brains of control rats and of rats after hepatectomy. We found that in most brain regions of hepatectomized rats there were increases in the concentration of 3,4-dihydroxyphenylalanine or of dopamine but decreases in the concentrations of norepinephrine or of 3,4-dihydroxyphenylglycol. The particulate/supernatant ratios of catecholamines are indices of retention of neurotransmitters in storage sites. These ratios were not different in brain regions between control rats and hepatectomized rats, suggesting that vesicular retention of catecholamines in brain was not impaired after hepatectomy. The data suggest that inhibition of dopamine-β-hydroxylase might be a characteristic of hepatic failure.     

GLYCOL SULPHATE ESTER FORMATION FROM [14C]NORADRENALINE IN BRAIN AND THE INFLUENCE OF A COMT INHIBITOR

A method is described allowing the identification and separation of the sulphate esters of the glycol metabolites of [¹⁴C]noradrenaline injected into the lateral ventricle of the rat. The esters of both the 3,4-dihydroxy derivative and the 3-methoxy-4-hydroxy derivative are formed in substantial amounts. It is suggested that the quantity of the former may have been underestimated in the past. Contemporaneous administration of pyrogallol, a catechol-O-methyl transferase inhibitor, with [¹⁴C] noradrenaline leads to a considerable fall in 3-methoxy-4-hydroxyphenylglycol sulphate without a rise in 3-4-dihydroxyphenylglycol sulphate although free 3-4-dihydroxyphenylglycol rises significantly. It is proposed that the latter may be an index of intraneuronal metabolism of noradrenaline and 3-methoxy-4-hydroxyphenylglycol that of released amine.     

Source and Physiological Significance of Plasma 3,4-Dihydroxyphenylalanine in the Rat

To elucidate the source and physiological significance of plasma 3,4-dihydroxyphenylalanine, the immediate product of the rate-limiting step in catecholamine biosynthesis, plasma 3,4-dihydroxyphenylalanine was quantified in conscious rats after administration of reserpine, desipramine, clorgyline, or forskolin, treatments that affect tyrosine hydroxylase activity. Plasma 3,4-dihydroxyphenylalanine was also examined during infusions of norepinephrine with or without clorgyline, reserpine, or desipramine pretreatment. After reserpine, the plasma 3,4-dihydroxyphenylalanine level decreased by 22% and then increased by 40%, a result consistent with modulation of tyrosine hydroxylase activity first by an increased axoplasmic norepinephrine content and then by depletion of norepinephrine stores. After desipramine, the plasma 3,4-dihydroxyphenylalanine level decreased by 20%, reflecting the depressant effect of neuronal uptake blockade on norepinephrine turnover. Forskolin increased the plasma 3,4-dihydroxyphenylalanine level by 30%, consistent with activation of tyrosine hydroxylase by cyclic AMP-dependent phosphorylation. Acute administration of clorgyline was without effect on the plasma 3,4-dihydroxyphenylalanine level. Norepinephrine infusions decreased the plasma 3,4-dihydroxyphenylalanine concentration, as expected from end-product inhibition of tyrosine hydroxylase. Pretreatment with desipramine prevented the norepinephrine-induced decrease in plasma dihydroxyphenylalanine content, indicating that inhibition of tyrosine hydroxylase required neuronal uptake of norepinephrine. Both reserpine and clorgyline augmented the norepinephrine-induced decrease in plasma 3,4-dihydroxyphenylalanine level, suggesting that retention of norepinephrine in the axoplasm--due to inhibition of norepinephrine sequestration into storage vesicles or catabolism--caused further inhibition of tyrosine hydroxylase. Changes in plasma 3,4-dihydroxyphenylalanine concentration during norepinephrine infusions were negatively correlated with those in plasma 3,4-dihydroxyphenylglycol level, a finding consistent with modulation of tyrosine hydroxylase activity by axoplasmic norepinephrine. In reserpinized animals, clorgyline and norepinephrine infusion together decreased the plasma 3,4-dihydroxyphenylalanine content by 50%, a result demonstrating that hydroxylation of tyrosine was depressed by at least half. The results indicate that quantification of plasma 3,4-dihydroxyphenylalanine can provide a simple and direct approach for examination of the rate-limiting step in catecholamine biosynthesis.     

Metergoline,pirenperone and pizotifen alter dopamine and 5-hydroxytryptamine synthesis in discrete rat brain nuclei

The effects of the 5-hydroxytryptamine receptor antagonists metergoline, pirenperone and pizotifen on 5-hydroxytryptamine and dopamine synthesis were determined by measuring the rate of accumulation of 5-hydroxytryptamine and 3,4-dihydroxyphenylalanine, respectively, after administering l-tryptophan and m-hydroxybenzylhydrazine, an inhibitor of aromatic-l-amino acid decarboxylase. 5-Hydroxytryptophan, 3,4-dihydroxyphenylalanine and l-tryptophan were measured in four forebrain regions, the caudate putamen, nucleus accumbens, nucleus septi lateralis, and nucleus amygdaloideus centralis, which contain terminals of 5-hydroxytryptamine and dopamine neurons. Metergoline increased 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine accumulation, and decreased l-tryptophan concentration in a dose- and time-dependent manner. Pirenperone increased 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine accumulation, but had no effect on l-tryptophan levels. These effects of pirenperone were time- and dose-related. Finally, pizotifen increased 5-hydroxytryptophan accumulation in a dose-related and time-dependent manner, but did not alter 3,4-dihydroxyphenylalanine or l-tryptophan concentrations. All the drug effects generally occurred in all four nuclei. These results suggest that 5-hydroxytryptamine receptor antagonists may affect synthesis in 5-hydroxytryptamine and/or dopamine neurons after l-tryptophan treatment and aromatic-l-amino acid decarboxylase inhibition.     

Inhibition of monoamine oxidase by amiloride

Amiloride was found to lower the overflow of 3,4-dihydroxyphenylethylene glycol from isolated rat tail artery. The overflow was reduced to about 50% in the presence of 10(-5) M concentration of the drug. Reduced overflows of the glycol were observed also under conditions when the nonexocytotic release of endogenous noradrenaline was enhanced by tyramine, reserpine, or by the elevation of external K+ in the absence of extracellular Ca2+. They were accompanied by increased overflows of the amine. Amiloride inhibited monoamine oxidase activity (E.C. 1.4.3.4) of the A form in rat brain homogenate by acting as a competitive inhibitor.     

Vesicular Storage of 3,4-Dihydroxyphenylethylamine and Noradrenaline in Terminal Sympathetic Nerves of Dog Spleen and Kidney

The subcellular distribution of 3,4-dihydroxyphenylethylamine (DA, dopamine) and noradrenaline was examined in preparations of dog spleen and renal cortex following ultracentrifugation on a discontinuous sucrose gradient. In both tissues, only half the total tissue DA was localized to the soluble phase, and 30-50% was found in association with noradrenaline in the large vesicular fraction, suggesting that both catecholamines may be stored together and released by nerve stimulation. The vesicular fraction from renal cortex contained more DA than could be attributed to its presence in noradrenergic axons alone, supporting other evidence for the existence of dopaminergic renal nerves.     

Determination of monoamines and 10 of their metabolites in the brain and heart of the rat by high-pressure liquid chromatography with electrochemical detection

The adequate parameters for simultaneous determination of more than 10 monoamines, their precursors and metabolites (noradrenaline, 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydrooxyphenylglycol++, vanylylmandelic acid, normetanephrine, adrenaline, metanephrine, dopamine, 3-methoxytytramine, 3,4-dihydroxphenylacetic acid, 3,4-dihydroxyphenylalanine, 5-hydroxytryptophane, 5-hydroxyindolacetic acid) by liquid chromatography with electro-chemical detection were suggested for the rat brain and heart. The influence of reserpine, iproniazid, and imipramine on the content of the changes of monoamines and their metabolite levels in the rat brain and heart were also investigated.     

Presynaptic Distribution of the Cholinergic-Specific Antigen Chol-1 and 5''-Nucleotidase in Rat Brain, as Determined by Complement-Mediated Release of Neurotransmitters

Nerve terminals prepared from rat cortex and hippocampus were loaded with seven radioactive putative neurotransmitters (serotonin, noradrenaline, dopamine, gamma-aminobutyric acid, aspartate, glutamate, and taurine). The release of these transmitters, choline acetyltransferase, 3,4-dihydroxyphenylalanine decarboxylase, enolase, and lactate dehydrogenase was monitored during complement-mediated lysis. Three antisera were used: anti-5'-nucleotidase, anti-Chol-1, and anti-rat cerebrum. Anti-5'-nucleotidase serum did not cause the release of any labelled transmitter or of any of the enzymes studied. Anti-Chol-1 serum released choline acetyltransferase and small amounts of enolase and lactate dehydrogenase. Anti-rat cerebrum caused the release of all seven transmitters, choline acetyltransferase, and small amounts of the other three enzymes. It was concluded that 5'-nucleotidase was not present on any of the terminals studied, and that Chol-1 is only present on cholinergic terminals.     

Electrophysiological research on the coupling of excitation-contraction during alpha-adrenoreceptor activation in blood vessel smooth muscles

Alpha 1-adrenoceptor blocker--prazosin--was found to inhibit noradrenaline-induced depolarization and concentration in the smooth muscles of the portal rabbit vein, indicating that this reaction was due to alpha 1-adrenoceptor activation. In the pulmonary artery both alpha 1 and alpha 2-adrenoceptors appear to be involved in noradrenaline excitatory action, as the effect was not completely inhibited by prazosin. The results suggest that hypotensive action of prazosin is related to the cessation of Ca2+ ion influx through alpha 1-operated calcium channels. The decrease in Ca2+ influx through voltage-dependent calcium channels due to prazosin-evoked elimination of depolarization can also contribute to this effect.     

Effects of chronic antidepressant treatment on nigrostriatal and mesolimbic dopamine autoreceptors in the rat

Dopamine autoreceptors were studied by determining the effects of chronic antidepressant treatment on the ability of several doses of apomorphine to decrease 3,4-dihydroxyphenylalanine accumulation (an index of dopamine synthesis in vivo) after saline or γ-hydroxybutyric acid lactone (γ-butyrolactone). 3,4-Dihydroxyphenylalanine accumulation was measured in nigrostriatal [nucleus caudatus putamen] and mesolimbic [nucleus accumbens and tuberculum olfactorium] nerve terminals. Apomorphine decreased 3,4-dihydroxyphenylalanine accumulation in the nucleus caudatus putamen, tuberculum olfactorium and nucleus accumbens in a dose-related manner. Chronic imipramine (10 days) treatment attenuated the low and high dose apomorphine-induced decrease in 3,4-dihydroxyphenylalanine accumulation in the nucleus caudatus putamen to a greater extent than the tuberculum olfactorium or nucleus accumbens. In γ-butyrolactone-treated animals chronic treatment with imipramine, amitriptyline or bupropion (10 days) attenuated the low dose apomorphine effect in the nucleus caudatus putamen, but not the tuberculum olfactorium or nucleus accumbens. Only 2 days of imipramine treatment had no effect on the apomorphine-induced decrease in 3,4-dihydroxyphenylalanine accumulation in the nucleus caudatus putamen with or without γ-butyrolactone treatment. These data suggest that chronic treatment with three antidepressants produces dopamine autoreceptor subsensitivity in nigrostriatal neurons more than mesolimbic neurons and that this effect is not seen with short-term imipramine treatment.     

Calcium Dependency and Tetrodotoxin Sensitivity of Neostriatal Dopamine Release in 5-Day-Old and Adult Rats as Measured by In Vivo Microdialysis

Abstract: The calcium dependency and tetrodotoxin sensitivity of extracellular dopamine levels were assessed by microdialysis in the neostriatum of 5-day-old rat pups and were compared with those obtained in adult rats. The removal of calcium from the dialysate reduced spontaneous levels of extracellular dopamine to 20% of normal in the 5-day-old pups and to 10% of normal in the adults. Calcium-free dialysate also decreased potassium-evoked dopamine release to ～20% of baseline in both ages. Furthermore, the addition of tetrodotoxin to the dialysate decreased spontaneous levels of extracellular dopamine to 10% of baseline in both ages. The effects of calcium removal and the addition of tetrodotoxin on extracellular levels of the dopamine metabolite 3,4-dihydroxyphenylacetic acid were less pronounced. The results of this study demonstrate that extracellular levels of dopamine sampled by microdialysis in rats as young as 5 days of age are both calcium dependent and tetrodotoxin sensitive; thus, they are derived from neuronal activity and not from injury caused by acute implantation of the probe. Other age-related differences support the hypothesis that dopamine release and turnover is greater In immature rats and may represent a form of compensation for incomplete dopamine nerve terminal ingrowth.     

Release and functional role of neuropeptide Y as a sympathetic modulator in human saphenous vein biopsies

Transmural electrical stimulation of the sympathetic nerve endings of human saphenous vein biopsies released two forms of NPY identified chromatographically as native and oxidized peptide. The release process is dependent on extracellular calcium, the frequency, and the duration of the stimuli. While guanethidine reduced the overflow of ir-NPY, phenoxybenzamine did not augment NPY release, but increased that of noradrenaline. Oxidized NPY, like native NPY, potentiated the noradrenaline and adenosine 5'-triphospahate-induced vasoconstriction, an effect blocked by BIBP 3226 and consonant with the RT-PCR detection of the mRNA encoding the NPY Y1 receptor. These results highlight the functional role of NPY in human vascular sympathetic reflexes.